img

Global Overactive Bladder Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Overactive Bladder Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Overactive Bladder Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Overactive Bladder Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Overactive Bladder Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Overactive Bladder Drug key manufacturers include Astellas Pharma, Inc. (Japan), Pfizer, Inc. (US), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (US), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan) and Sanofi (France), etc. Astellas Pharma, Inc. (Japan), Pfizer, Inc. (US), Teva Pharmaceutical Industries Limited (Israel) are top 3 players and held % sales share in total in 2022.
Overactive Bladder Drug can be divided into Anticholinergics, Solifenacin, Oxybutynin and Darifenacin, etc. Anticholinergics is the mainstream product in the market, accounting for % sales share globally in 2022.
Overactive Bladder Drug is widely used in various fields, such as Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity, etc. Idiopathic Bladder Overactivity provides greatest supports to the Overactive Bladder Drug industry development. In 2022, global % sales of Overactive Bladder Drug went into Idiopathic Bladder Overactivity filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Overactive Bladder Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Astellas Pharma, Inc. (Japan)
Pfizer, Inc. (US)
Teva Pharmaceutical Industries Limited (Israel)
Allergan, Plc (Ireland)
Medtronic plc (Ireland)
Mylan N.V. (US)
Endo International plc (Ireland)
Hisamitsu Pharmaceutical Co., Inc. (Japan)
Sanofi (France)
Apotex, Inc. (Canada)
Cogentix Medical, Inc. (US)
Aurobindo Pharma Limited (India)
Segment by Type
Anticholinergics
Solifenacin
Oxybutynin
Darifenacin
Fesoterodine
Tolterodine
Trospium
Others

Segment by Application


Idiopathic Bladder Overactivity
Neurogenic Bladder Overactivity

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Overactive Bladder Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Overactive Bladder Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Overactive Bladder Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Overactive Bladder Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Overactive Bladder Drug introduction, etc. Overactive Bladder Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Overactive Bladder Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Overactive Bladder Drug Market Overview
1.1 Overactive Bladder Drug Product Overview
1.2 Overactive Bladder Drug Market Segment by Type
1.2.1 Anticholinergics
1.2.2 Solifenacin
1.2.3 Oxybutynin
1.2.4 Darifenacin
1.2.5 Fesoterodine
1.2.6 Tolterodine
1.2.7 Trospium
1.2.8 Others
1.3 Global Overactive Bladder Drug Market Size by Type
1.3.1 Global Overactive Bladder Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Overactive Bladder Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Overactive Bladder Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Overactive Bladder Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Overactive Bladder Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Overactive Bladder Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Overactive Bladder Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Overactive Bladder Drug Sales Breakdown by Type (2018-2024)
2 Global Overactive Bladder Drug Market Competition by Company
2.1 Global Top Players by Overactive Bladder Drug Sales (2018-2024)
2.2 Global Top Players by Overactive Bladder Drug Revenue (2018-2024)
2.3 Global Top Players by Overactive Bladder Drug Price (2018-2024)
2.4 Global Top Manufacturers Overactive Bladder Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Overactive Bladder Drug Market Competitive Situation and Trends
2.5.1 Overactive Bladder Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Overactive Bladder Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Overactive Bladder Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Overactive Bladder Drug Market
2.8 Key Manufacturers Overactive Bladder Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Overactive Bladder Drug Status and Outlook by Region
3.1 Global Overactive Bladder Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Overactive Bladder Drug Historic Market Size by Region
3.2.1 Global Overactive Bladder Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Overactive Bladder Drug Sales in Value by Region (2018-2024)
3.2.3 Global Overactive Bladder Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Overactive Bladder Drug Forecasted Market Size by Region
3.3.1 Global Overactive Bladder Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Overactive Bladder Drug Sales in Value by Region (2024-2034)
3.3.3 Global Overactive Bladder Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Overactive Bladder Drug by Application
4.1 Overactive Bladder Drug Market Segment by Application
4.1.1 Idiopathic Bladder Overactivity
4.1.2 Neurogenic Bladder Overactivity
4.2 Global Overactive Bladder Drug Market Size by Application
4.2.1 Global Overactive Bladder Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Overactive Bladder Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Overactive Bladder Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Overactive Bladder Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Overactive Bladder Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Overactive Bladder Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Overactive Bladder Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Overactive Bladder Drug Sales Breakdown by Application (2018-2024)
5 North America Overactive Bladder Drug by Country
5.1 North America Overactive Bladder Drug Historic Market Size by Country
5.1.1 North America Overactive Bladder Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Overactive Bladder Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Overactive Bladder Drug Sales in Value by Country (2018-2024)
5.2 North America Overactive Bladder Drug Forecasted Market Size by Country
5.2.1 North America Overactive Bladder Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Overactive Bladder Drug Sales in Value by Country (2024-2034)
6 Europe Overactive Bladder Drug by Country
6.1 Europe Overactive Bladder Drug Historic Market Size by Country
6.1.1 Europe Overactive Bladder Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Overactive Bladder Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Overactive Bladder Drug Sales in Value by Country (2018-2024)
6.2 Europe Overactive Bladder Drug Forecasted Market Size by Country
6.2.1 Europe Overactive Bladder Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Overactive Bladder Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Overactive Bladder Drug by Region
7.1 Asia-Pacific Overactive Bladder Drug Historic Market Size by Region
7.1.1 Asia-Pacific Overactive Bladder Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Overactive Bladder Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Overactive Bladder Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Overactive Bladder Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Overactive Bladder Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Overactive Bladder Drug Sales in Value by Region (2024-2034)
8 Latin America Overactive Bladder Drug by Country
8.1 Latin America Overactive Bladder Drug Historic Market Size by Country
8.1.1 Latin America Overactive Bladder Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Overactive Bladder Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Overactive Bladder Drug Sales in Value by Country (2018-2024)
8.2 Latin America Overactive Bladder Drug Forecasted Market Size by Country
8.2.1 Latin America Overactive Bladder Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Overactive Bladder Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Overactive Bladder Drug by Country
9.1 Middle East and Africa Overactive Bladder Drug Historic Market Size by Country
9.1.1 Middle East and Africa Overactive Bladder Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Overactive Bladder Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Overactive Bladder Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Overactive Bladder Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Overactive Bladder Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Overactive Bladder Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Astellas Pharma, Inc. (Japan)
10.1.1 Astellas Pharma, Inc. (Japan) Company Information
10.1.2 Astellas Pharma, Inc. (Japan) Introduction and Business Overview
10.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Products Offered
10.1.5 Astellas Pharma, Inc. (Japan) Recent Development
10.2 Pfizer, Inc. (US)
10.2.1 Pfizer, Inc. (US) Company Information
10.2.2 Pfizer, Inc. (US) Introduction and Business Overview
10.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Pfizer, Inc. (US) Overactive Bladder Drug Products Offered
10.2.5 Pfizer, Inc. (US) Recent Development
10.3 Teva Pharmaceutical Industries Limited (Israel)
10.3.1 Teva Pharmaceutical Industries Limited (Israel) Company Information
10.3.2 Teva Pharmaceutical Industries Limited (Israel) Introduction and Business Overview
10.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Products Offered
10.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Development
10.4 Allergan, Plc (Ireland)
10.4.1 Allergan, Plc (Ireland) Company Information
10.4.2 Allergan, Plc (Ireland) Introduction and Business Overview
10.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Allergan, Plc (Ireland) Overactive Bladder Drug Products Offered
10.4.5 Allergan, Plc (Ireland) Recent Development
10.5 Medtronic plc (Ireland)
10.5.1 Medtronic plc (Ireland) Company Information
10.5.2 Medtronic plc (Ireland) Introduction and Business Overview
10.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Medtronic plc (Ireland) Overactive Bladder Drug Products Offered
10.5.5 Medtronic plc (Ireland) Recent Development
10.6 Mylan N.V. (US)
10.6.1 Mylan N.V. (US) Company Information
10.6.2 Mylan N.V. (US) Introduction and Business Overview
10.6.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Mylan N.V. (US) Overactive Bladder Drug Products Offered
10.6.5 Mylan N.V. (US) Recent Development
10.7 Endo International plc (Ireland)
10.7.1 Endo International plc (Ireland) Company Information
10.7.2 Endo International plc (Ireland) Introduction and Business Overview
10.7.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Endo International plc (Ireland) Overactive Bladder Drug Products Offered
10.7.5 Endo International plc (Ireland) Recent Development
10.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
10.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Information
10.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Introduction and Business Overview
10.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Products Offered
10.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Development
10.9 Sanofi (France)
10.9.1 Sanofi (France) Company Information
10.9.2 Sanofi (France) Introduction and Business Overview
10.9.3 Sanofi (France) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Sanofi (France) Overactive Bladder Drug Products Offered
10.9.5 Sanofi (France) Recent Development
10.10 Apotex, Inc. (Canada)
10.10.1 Apotex, Inc. (Canada) Company Information
10.10.2 Apotex, Inc. (Canada) Introduction and Business Overview
10.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Apotex, Inc. (Canada) Overactive Bladder Drug Products Offered
10.10.5 Apotex, Inc. (Canada) Recent Development
10.11 Cogentix Medical, Inc. (US)
10.11.1 Cogentix Medical, Inc. (US) Company Information
10.11.2 Cogentix Medical, Inc. (US) Introduction and Business Overview
10.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Cogentix Medical, Inc. (US) Overactive Bladder Drug Products Offered
10.11.5 Cogentix Medical, Inc. (US) Recent Development
10.12 Aurobindo Pharma Limited (India)
10.12.1 Aurobindo Pharma Limited (India) Company Information
10.12.2 Aurobindo Pharma Limited (India) Introduction and Business Overview
10.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Aurobindo Pharma Limited (India) Overactive Bladder Drug Products Offered
10.12.5 Aurobindo Pharma Limited (India) Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Overactive Bladder Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Overactive Bladder Drug Industrial Chain Analysis
11.4 Overactive Bladder Drug Market Dynamics
11.4.1 Overactive Bladder Drug Industry Trends
11.4.2 Overactive Bladder Drug Market Drivers
11.4.3 Overactive Bladder Drug Market Challenges
11.4.4 Overactive Bladder Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Overactive Bladder Drug Distributors
12.3 Overactive Bladder Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Anticholinergics
Table 2. Major Company of Solifenacin
Table 3. Major Company of Oxybutynin
Table 4. Major Company of Darifenacin
Table 5. Major Company of Fesoterodine
Table 6. Major Company of Tolterodine
Table 7. Major Company of Trospium
Table 8. Major Company of Others
Table 9. Global Overactive Bladder Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 10. Global Overactive Bladder Drug Sales by Type (2018-2024) & (K Units)
Table 11. Global Overactive Bladder Drug Sales Market Share in Volume by Type (2018-2024)
Table 12. Global Overactive Bladder Drug Sales by Type (2018-2024) & (US& Million)
Table 13. Global Overactive Bladder Drug Market Share in Value by Type (2018-2024)
Table 14. Global Overactive Bladder Drug Price by Type (2018-2024) & (USD/Unit)
Table 15. Global Overactive Bladder Drug Sales by Type (2024-2034) & (K Units)
Table 16. Global Overactive Bladder Drug Sales Market Share in Volume by Type (2024-2034)
Table 17. Global Overactive Bladder Drug Sales by Type (2024-2034) & (US$ Million)
Table 18. Global Overactive Bladder Drug Sales Market Share in Value by Type (2024-2034)
Table 19. Global Overactive Bladder Drug Price by Type (2024-2034) & (USD/Unit)
Table 20. North America Overactive Bladder Drug Sales by Type (2018-2024) & (K Units)
Table 21. North America Overactive Bladder Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Europe Overactive Bladder Drug Sales (K Units) by Type (2018-2024)
Table 23. Europe Overactive Bladder Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Asia-Pacific Overactive Bladder Drug Sales (K Units) by Type (2018-2024)
Table 25. Asia-Pacific Overactive Bladder Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Latin America Overactive Bladder Drug Sales (K Units) by Type (2018-2024)
Table 27. Latin America Overactive Bladder Drug Sales by Type (2018-2024) & (US$ Million)
Table 28. Middle East and Africa Overactive Bladder Drug Sales (K Units) by Type (2018-2024)
Table 29. Middle East and Africa Overactive Bladder Drug Sales by Type (2018-2024) & (US$ Million)
Table 30. Global Overactive Bladder Drug Sales by Company (2018-2024) & (K Units)
Table 31. Global Overactive Bladder Drug Sales Share by Company (2018-2024)
Table 32. Global Overactive Bladder Drug Revenue by Company (2018-2024) & (US$ Million)
Table 33. Global Overactive Bladder Drug Revenue Share by Company (2018-2024)
Table 34. Global Market Overactive Bladder Drug Price by Company (2018-2024) & (USD/Unit)
Table 35. Global Overactive Bladder Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 36. Global Overactive Bladder Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 37. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Overactive Bladder Drug as of 2022)
Table 38. Date of Key Manufacturers Enter into Overactive Bladder Drug Market
Table 39. Key Manufacturers Overactive Bladder Drug Product Type
Table 40. Mergers & Acquisitions, Expansion Plans
Table 41. Global Overactive Bladder Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 42. Global Overactive Bladder Drug Sales by Region (2018-2024) & (K Units)
Table 43. Global Overactive Bladder Drug Sales Market Share in Volume by Region (2018-2024)
Table 44. Global Overactive Bladder Drug Sales by Region (2018-2024) & (US$ Million)
Table 45. Global Overactive Bladder Drug Sales Market Share in Value by Region (2018-2024)
Table 46. Global Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 47. Global Overactive Bladder Drug Sales by Region (2024-2034) & (K Units)
Table 48. Global Overactive Bladder Drug Sales Market Share in Volume by Region (2024-2034)
Table 49. Global Overactive Bladder Drug Sales by Region (2024-2034) & (US$ Million)
Table 50. Global Overactive Bladder Drug Sales Market Share in Value by Region (2024-2034)
Table 51. Global Overactive Bladder Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2034)
Table 52. Global Overactive Bladder Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 53. Global Overactive Bladder Drug Sales by Application (2018-2024) & (K Units)
Table 54. Global Overactive Bladder Drug Sales Market Share in Volume by Application (2018-2024)
Table 55. Global Overactive Bladder Drug Sales by Application (2018-2024) & (US$ Million)
Table 56. Global Overactive Bladder Drug Sales Market Share in Value by Application (2018-2024)
Table 57. Global Overactive Bladder Drug Price by Application (2018-2024) & (USD/Unit)
Table 58. Global Overactive Bladder Drug Sales by Application (2024-2034) & (K Units)
Table 59. Global Overactive Bladder Drug Sales Market Share in Volume by Application (2024-2034)
Table 60. Global Overactive Bladder Drug Sales by Application (2024-2034) & (US$ Million)
Table 61. Global Overactive Bladder Drug Sales Market Share in Value by Application (2024-2034)
Table 62. Global Overactive Bladder Drug Price by Application (2024-2034) & (USD/Unit)
Table 63. North America Overactive Bladder Drug Sales by Application (2018-2024) (K Units)
Table 64. North America Overactive Bladder Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Europe Overactive Bladder Drug Sales by Application (2018-2024) (K Units)
Table 66. Europe Overactive Bladder Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Asia-Pacific Overactive Bladder Drug Sales by Application (2018-2024) (K Units)
Table 68. Asia-Pacific Overactive Bladder Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. Latin America Overactive Bladder Drug Sales by Application (2018-2024) (K Units)
Table 70. Latin America Overactive Bladder Drug Sales by Application (2018-2024) & (US$ Million)
Table 71. Middle East and Africa Overactive Bladder Drug Sales by Application (2018-2024) (K Units)
Table 72. Middle East and Africa Overactive Bladder Drug Sales by Application (2018-2024) & (US$ Million)
Table 73. North America Overactive Bladder Drug Sales by Country (2018-2024) & (K Units)
Table 74. North America Overactive Bladder Drug Sales Market Share in Volume by Country (2018-2024)
Table 75. North America Overactive Bladder Drug Sales by Country (2018-2024) & (US$ Million)
Table 76. North America Overactive Bladder Drug Sales Market Share in Value by Country (2018-2024)
Table 77. North America Overactive Bladder Drug Sales by Country (2024-2034) & (K Units)
Table 78. North America Overactive Bladder Drug Sales Market Share in Volume by Country (2024-2034)
Table 79. North America Overactive Bladder Drug Sales by Country (2024-2034) & (US$ Million)
Table 80. North America Overactive Bladder Drug Sales Market Share in Value by Country (2024-2034)
Table 81. Europe Overactive Bladder Drug Sales by Country (2018-2024) & (K Units)
Table 82. Europe Overactive Bladder Drug Sales Market Share in Volume by Country (2018-2024)
Table 83. Europe Overactive Bladder Drug Sales by Country (2018-2024) & (US$ Million)
Table 84. Europe Overactive Bladder Drug Sales Market Share in Value by Country (2018-2024)
Table 85. Europe Overactive Bladder Drug Sales by Country (2024-2034) & (K Units)
Table 86. Europe Overactive Bladder Drug Sales Market Share in Volume by Country (2024-2034)
Table 87. Europe Overactive Bladder Drug Sales by Country (2024-2034) & (US$ Million)
Table 88. Europe Overactive Bladder Drug Sales Market Share in Value by Country (2024-2034)
Table 89. Asia-Pacific Overactive Bladder Drug Sales by Region (2018-2024) & (K Units)
Table 90. Asia-Pacific Overactive Bladder Drug Sales Market Share in Volume by Region (2018-2024)
Table 91. Asia-Pacific Overactive Bladder Drug Sales by Region (2018-2024) & (US$ Million)
Table 92. Asia-Pacific Overactive Bladder Drug Sales Market Share in Value by Region (2018-2024)
Table 93. Asia-Pacific Overactive Bladder Drug Sales by Region (2024-2034) & (K Units)
Table 94. Asia-Pacific Overactive Bladder Drug Sales Market Share in Volume by Region (2024-2034)
Table 95. Asia-Pacific Overactive Bladder Drug Sales by Region (2024-2034) & (US$ Million)
Table 96. Asia-Pacific Overactive Bladder Drug Sales Market Share in Value by Region (2024-2034)
Table 97. Latin America Overactive Bladder Drug Sales by Country (2018-2024) & (K Units)
Table 98. Latin America Overactive Bladder Drug Sales Market Share in Volume by Country (2018-2024)
Table 99. Latin America Overactive Bladder Drug Sales by Country (2018-2024) & (US$ Million)
Table 100. Latin America Overactive Bladder Drug Sales Market Share in Value by Country (2018-2024)
Table 101. Latin America Overactive Bladder Drug Sales by Country (2024-2034) & (K Units)
Table 102. Latin America Overactive Bladder Drug Sales Market Share in Volume by Country (2024-2034)
Table 103. Latin America Overactive Bladder Drug Sales by Country (2024-2034) & (US$ Million)
Table 104. Latin America Overactive Bladder Drug Sales Market Share in Value by Country (2024-2034)
Table 105. Middle East and Africa Overactive Bladder Drug Sales by Country (2018-2024) & (K Units)
Table 106. Middle East and Africa Overactive Bladder Drug Sales Market Share in Volume by Country (2018-2024)
Table 107. Middle East and Africa Overactive Bladder Drug Sales by Country (2018-2024) & (US$ Million)
Table 108. Middle East and Africa Overactive Bladder Drug Sales Market Share in Value by Country (2018-2024)
Table 109. Middle East and Africa Overactive Bladder Drug Sales by Country (2024-2034) & (K Units)
Table 110. Middle East and Africa Overactive Bladder Drug Sales Market Share in Volume by Country (2024-2034)
Table 111. Middle East and Africa Overactive Bladder Drug Sales by Country (2024-2034) & (US$ Million)
Table 112. Middle East and Africa Overactive Bladder Drug Sales Market Share in Value by Country (2024-2034)
Table 113. Astellas Pharma, Inc. (Japan) Company Information
Table 114. Astellas Pharma, Inc. (Japan) Introduction and Business Overview
Table 115. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 116. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product
Table 117. Astellas Pharma, Inc. (Japan) Recent Development
Table 118. Pfizer, Inc. (US) Company Information
Table 119. Pfizer, Inc. (US) Introduction and Business Overview
Table 120. Pfizer, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 121. Pfizer, Inc. (US) Overactive Bladder Drug Product
Table 122. Pfizer, Inc. (US) Recent Development
Table 123. Teva Pharmaceutical Industries Limited (Israel) Company Information
Table 124. Teva Pharmaceutical Industries Limited (Israel) Introduction and Business Overview
Table 125. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 126. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product
Table 127. Teva Pharmaceutical Industries Limited (Israel) Recent Development
Table 128. Allergan, Plc (Ireland) Company Information
Table 129. Allergan, Plc (Ireland) Introduction and Business Overview
Table 130. Allergan, Plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 131. Allergan, Plc (Ireland) Overactive Bladder Drug Product
Table 132. Allergan, Plc (Ireland) Recent Development
Table 133. Medtronic plc (Ireland) Company Information
Table 134. Medtronic plc (Ireland) Introduction and Business Overview
Table 135. Medtronic plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 136. Medtronic plc (Ireland) Overactive Bladder Drug Product
Table 137. Medtronic plc (Ireland) Recent Development
Table 138. Mylan N.V. (US) Company Information
Table 139. Mylan N.V. (US) Introduction and Business Overview
Table 140. Mylan N.V. (US) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 141. Mylan N.V. (US) Overactive Bladder Drug Product
Table 142. Mylan N.V. (US) Recent Development
Table 143. Endo International plc (Ireland) Company Information
Table 144. Endo International plc (Ireland) Introduction and Business Overview
Table 145. Endo International plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 146. Endo International plc (Ireland) Overactive Bladder Drug Product
Table 147. Endo International plc (Ireland) Recent Development
Table 148. Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Information
Table 149. Hisamitsu Pharmaceutical Co., Inc. (Japan) Introduction and Business Overview
Table 150. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 151. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product
Table 152. Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Development
Table 153. Sanofi (France) Company Information
Table 154. Sanofi (France) Introduction and Business Overview
Table 155. Sanofi (France) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 156. Sanofi (France) Overactive Bladder Drug Product
Table 157. Sanofi (France) Recent Development
Table 158. Apotex, Inc. (Canada) Company Information
Table 159. Apotex, Inc. (Canada) Introduction and Business Overview
Table 160. Apotex, Inc. (Canada) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 161. Apotex, Inc. (Canada) Overactive Bladder Drug Product
Table 162. Apotex, Inc. (Canada) Recent Development
Table 163. Cogentix Medical, Inc. (US) Company Information
Table 164. Cogentix Medical, Inc. (US) Introduction and Business Overview
Table 165. Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 166. Cogentix Medical, Inc. (US) Overactive Bladder Drug Product
Table 167. Cogentix Medical, Inc. (US) Recent Development
Table 168. Aurobindo Pharma Limited (India) Company Information
Table 169. Aurobindo Pharma Limited (India) Introduction and Business Overview
Table 170. Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 171. Aurobindo Pharma Limited (India) Overactive Bladder Drug Product
Table 172. Aurobindo Pharma Limited (India) Recent Development
Table 173. Key Raw Materials Lists
Table 174. Raw Materials Key Suppliers Lists
Table 175. Overactive Bladder Drug Market Trends
Table 176. Overactive Bladder Drug Market Drivers
Table 177. Overactive Bladder Drug Market Challenges
Table 178. Overactive Bladder Drug Market Restraints
Table 179. Overactive Bladder Drug Distributors List
Table 180. Overactive Bladder Drug Downstream Customers
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources
List of Figures
Figure 1. Overactive Bladder Drug Product Picture
Figure 2. Global Overactive Bladder Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Overactive Bladder Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Overactive Bladder Drug Sales Status and Outlook (2018-2034) & (K Units)
Figure 5. Product Picture of Anticholinergics
Figure 6. Global Anticholinergics Sales YoY Growth (2018-2034) & (K Units)
Figure 7. Product Picture of Solifenacin
Figure 8. Global Solifenacin Sales YoY Growth (2018-2034) & (K Units)
Figure 9. Product Picture of Oxybutynin
Figure 10. Global Oxybutynin Sales YoY Growth (2018-2034) & (K Units)
Figure 11. Product Picture of Darifenacin
Figure 12. Global Darifenacin Sales YoY Growth (2018-2034) & (K Units)
Figure 13. Product Picture of Fesoterodine
Figure 14. Global Fesoterodine Sales YoY Growth (2018-2034) & (K Units)
Figure 15. Product Picture of Tolterodine
Figure 16. Global Tolterodine Sales YoY Growth (2018-2034) & (K Units)
Figure 17. Product Picture of Trospium
Figure 18. Global Trospium Sales YoY Growth (2018-2034) & (K Units)
Figure 19. Product Picture of Others
Figure 20. Global Others Sales YoY Growth (2018-2034) & (K Units)
Figure 21. Global Overactive Bladder Drug Sales by Type (2018-2034) & (US$ Million)
Figure 22. Global Overactive Bladder Drug Sales Market Share by Type in 2022 & 2034
Figure 23. North America Overactive Bladder Drug Sales Market Share in Volume by Type in 2022
Figure 24. North America Overactive Bladder Drug Sales Market Share in Value by Type in 2022
Figure 25. Europe Overactive Bladder Drug Sales Market Share in Volume by Type in 2022
Figure 26. Europe Overactive Bladder Drug Sales Market Share in Value by Type in 2022
Figure 27. Asia-Pacific Overactive Bladder Drug Sales Market Share in Volume by Type in 2022
Figure 28. Asia-Pacific Overactive Bladder Drug Sales Market Share in Value by Type in 2022
Figure 29. Latin America Overactive Bladder Drug Sales Market Share in Volume by Type in 2022
Figure 30. Latin America Overactive Bladder Drug Sales Market Share in Value by Type in 2022
Figure 31. Middle East and Africa Overactive Bladder Drug Sales Market Share in Volume by Type in 2022
Figure 32. Middle East and Africa Overactive Bladder Drug Sales Market Share in Value by Type in 2022
Figure 33. The 5 and 10 Largest Manufacturers in the World: Market Share by Overactive Bladder Drug Sales in 2022
Figure 34. The 5 and 10 Largest Manufacturers in the World: Market Share by Overactive Bladder Drug Revenue in 2022
Figure 35. Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 36. Product Picture of Idiopathic Bladder Overactivity
Figure 37. Global Idiopathic Bladder Overactivity Sales YoY Growth (2018-2034) & (K Units)
Figure 38. Product Picture of Neurogenic Bladder Overactivity
Figure 39. Global Neurogenic Bladder Overactivity Sales YoY Growth (2018-2034) & (K Units)
Figure 40. Global Overactive Bladder Drug Sales by Application (2018-2034) & (US$ Million)
Figure 41. Global Overactive Bladder Drug Sales Market Share by Application in 2022 & 2034
Figure 42. North America Overactive Bladder Drug Sales Market Share in Volume by Application in 2022
Figure 43. North America Overactive Bladder Drug Sales Market Share in Value by Application in 2022
Figure 44. Europe Overactive Bladder Drug Sales Market Share in Volume by Application in 2022
Figure 45. Europe Overactive Bladder Drug Sales Market Share in Value by Application in 2022
Figure 46. Asia-Pacific Overactive Bladder Drug Sales Market Share in Volume by Application in 2022
Figure 47. Asia-Pacific Overactive Bladder Drug Sales Market Share in Value by Application in 2022
Figure 48. Latin America Overactive Bladder Drug Sales Market Share in Volume by Application in 2022
Figure 49. Latin America Overactive Bladder Drug Sales Market Share in Value by Application in 2022
Figure 50. Middle East and Africa Overactive Bladder Drug Sales Market Share in Value by Application in 2022
Figure 51. Key Raw Materials Price
Figure 52. Overactive Bladder Drug Manufacturing Cost Structure
Figure 53. Overactive Bladder Drug Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries